Summit Financial Strategies Inc. cut its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,400 shares of the company’s stock after selling 226 shares during the period. Summit Financial Strategies Inc.’s holdings in Merck & Co., Inc. were worth $669,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 3.8% during the fourth quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock valued at $9,331,676,000 after acquiring an additional 3,153,333 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after purchasing an additional 4,731,152 shares in the last quarter. Norges Bank acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $3,108,366,000. Royal Bank of Canada boosted its holdings in Merck & Co., Inc. by 12.8% during the fourth quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock valued at $1,632,255,000 after purchasing an additional 1,696,151 shares in the last quarter. Finally, Capital World Investors boosted its holdings in Merck & Co., Inc. by 67.6% during the first quarter. Capital World Investors now owns 13,954,017 shares of the company’s stock valued at $1,841,233,000 after purchasing an additional 5,627,923 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Trading Up 0.3 %
Shares of MRK traded up $0.36 during trading hours on Friday, reaching $113.67. The stock had a trading volume of 10,102,341 shares, compared to its average volume of 8,717,050. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $134.63. The firm has a 50-day moving average of $123.83 and a 200 day moving average of $126.05. The company has a market cap of $287.90 billion, a P/E ratio of 126.30, a P/E/G ratio of 1.57 and a beta of 0.38.
Merck & Co., Inc. Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date is Monday, September 16th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.
Analysts Set New Price Targets
MRK has been the topic of several recent analyst reports. UBS Group reduced their target price on Merck & Co., Inc. from $148.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Truist Financial boosted their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Barclays reduced their target price on Merck & Co., Inc. from $145.00 to $142.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Finally, Wolfe Research upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Buy” and an average target price of $134.58.
Read Our Latest Analysis on MRK
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Market Cap Calculator: How to Calculate Market Cap
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.